Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company specializing in Antibody Drug Conjugates (ADCs), announced that shareholders approved all management proposals with a large majority at the company's ordinary virtual Annual General Meeting held on June 23, 2026. The voting results ranged between 98.67% and 98.72% in favor of the resolutions, reflecting strong shareholder support for the company's strategic direction.
The meeting saw the formal approval of the actions of the Management Board and Supervisory Board for the 2024/2025 financial year, the appointment of auditors for the 2025/2026 financial year, and the approval of the remuneration report for the Management Board. A key resolution was the election of Mr. Jack Yefei Ling as a new member of the Supervisory Board, bringing fresh expertise to the board. Additionally, shareholders approved an amendment to the Articles of Association to reduce the size of the Supervisory Board from seven to five members, a move aimed at streamlining governance.
Attendance at the meeting, including postal votes, reached 80.55% of the current capital stock, indicating high shareholder engagement. Detailed voting results are available on the company's website at https://heidelberg-pharma.com/en/agm.
Heidelberg Pharma is pioneering the use of Amanitin, a toxin derived from the green death cap mushroom, as a novel therapeutic modality in its ATAC technology platform. The company's lead candidate, HDP-101 (INN: pamlectabart tismanitin), targets BCMA for multiple myeloma and has received Orphan Drug Designation and Fast Track Designation from the U.S. Food and Drug Administration. A second candidate, HDP-102, is in clinical development for Non-Hodgkin Lymphoma, while HDP-103 and HDP-104 are in preclinical stages for metastatic castration-resistant prostate cancer and gastrointestinal tumors, respectively. These programs are available for partnering.
The company, headquartered in Ladenburg, Germany, is listed on the Frankfurt Stock Exchange under the symbol HPHA. More information about Heidelberg Pharma and its ATAC technology can be found at www.heidelberg-pharma.com. The approval of all agenda items and the election of a new supervisory board member underscore shareholder confidence in Heidelberg Pharma's strategy to advance its innovative ADC platform and pipeline.
